• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    12/6/21 4:32:02 PM ET
    $ACAD
    $APTX
    $CPIX
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACAD alert in real time by email

    Gainers

    • ACADIA Pharmaceuticals (NASDAQ:ACAD) stock rose 24.26% to $24.11 during Monday's after-market session. Today's trading volume for this security ended up closing at 1.3 million shares, which is 106.1 percent of its average volume over the last 100 days. The company's market cap stands at $3.8 billion.
    • Cumberland (NASDAQ:CPIX) stock increased by 8.64% to $7.54. At the close, Cumberland's trading volume reached 638.8K shares. This is 16.19% of its average volume over the last 100 days. The company's market cap stands at $111.6 million.
    • Aptinyx (NASDAQ:APTX) stock moved upwards by 8.29% to $2.35. The market value of their outstanding shares is at $159.1 million.
    • TherapeuticsMD (NASDAQ:TXMD) shares increased by 7.99% to $0.41. Today's trading volume for this security ended up closing at 306.9K shares, which is 6.77 percent of its average volume over the last 100 days. The company's market cap stands at $173.9 million.
    • Quidel (NASDAQ:QDEL) stock moved upwards by 4.33% to $145.75. The company's market cap stands at $6.0 billion.
    • OncoSec Medical (NASDAQ:ONCS) shares moved upwards by 4.03% to $1.29. The company's market cap stands at $50.5 million.

    Losers

    • HealthEquity (NASDAQ:HQY) shares fell 17.39% to $46.82 during Monday's after-market session. HealthEquity's trading volume hit 92.0K shares by close, accounting for 19.61% of its average volume over the last 100 days. The company's market cap stands at $3.9 billion. As per the press release, Q3 earnings came out today.
    • Ontrak (NASDAQ:OTRK) shares decreased by 8.35% to $5.49. The company's market cap stands at $105.2 million.
    • Galera Therapeutics (NASDAQ:GRTX) stock decreased by 5.47% to $1.21. The market value of their outstanding shares is at $31.9 million.
    • Ocuphire Pharma (NASDAQ:OCUP) stock declined by 5.16% to $3.31. The market value of their outstanding shares is at $57.2 million.
    • OptiNose (NASDAQ:OPTN) stock declined by 4.22% to $1.59. The company's market cap stands at $130.6 million.
    • ZIOPHARM Oncology (NASDAQ:ZIOP) shares declined by 3.97% to $1.21. Trading volume for this security closed at 208.4K, accounting for 6.13% of its average full-day volume over the last 100 days. The company's market cap stands at $261.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACAD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAD
    $APTX
    $CPIX
    $GRTX

    CompanyDatePrice TargetRatingAnalyst
    ACADIA Pharmaceuticals Inc.
    $ACAD
    3/25/2026$29.00Neutral → Buy
    BofA Securities
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/24/2026$33.00Outperform
    Wolfe Research
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/23/2026$35.00Neutral → Outperform
    Mizuho
    HealthEquity Inc.
    $HQY
    1/9/2026$89.00Neutral → Sell
    Goldman
    HealthEquity Inc.
    $HQY
    12/9/2025$118.00Overweight
    Barclays
    HealthEquity Inc.
    $HQY
    11/13/2025$100.00Market Perform
    BMO Capital Markets
    ACADIA Pharmaceuticals Inc.
    $ACAD
    10/21/2025$33.00Buy
    Citigroup
    QuidelOrtho Corporation
    $QDEL
    10/7/2025$33.00Buy → Neutral
    Citigroup
    More analyst ratings

    $ACAD
    $APTX
    $CPIX
    $GRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)

    4/A - QuidelOrtho Corp (0001906324) (Issuer)

    2/19/26 4:18:05 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Strobeck Matthew bought $239,586 worth of shares (10,000 units at $23.96), increasing direct ownership by 56% to 27,775 units (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/13/26 4:20:08 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Busky Joseph M. bought $79,742 worth of shares (3,370 units at $23.66) (SEC Form 4)

    4 - QuidelOrtho Corp (0001906324) (Issuer)

    2/13/26 12:44:31 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACAD
    $APTX
    $CPIX
    $GRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ACADIA Pharmaceuticals upgraded by BofA Securities with a new price target

    BofA Securities upgraded ACADIA Pharmaceuticals from Neutral to Buy and set a new price target of $29.00

    3/25/26 8:22:46 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on ACADIA Pharmaceuticals with a new price target

    Wolfe Research initiated coverage of ACADIA Pharmaceuticals with a rating of Outperform and set a new price target of $33.00

    2/24/26 7:44:56 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACADIA Pharmaceuticals upgraded by Mizuho with a new price target

    Mizuho upgraded ACADIA Pharmaceuticals from Neutral to Outperform and set a new price target of $35.00

    2/23/26 8:28:41 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $APTX
    $CPIX
    $GRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for RYZUMVI issued to OCUPHIRE PHARMA INC

    Submission status for OCUPHIRE PHARMA INC's drug RYZUMVI (ORIG-1) with active ingredient PHENTOLAMINE has changed to 'Approval' on 09/25/2023. Application Category: NDA, Application Number: 217064, Application Classification: Type 3 - New Dosage Form

    9/26/23 12:02:02 PM ET
    $OCUP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

    9/18/23 10:47:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

    9/18/23 10:40:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $APTX
    $CPIX
    $GRTX
    SEC Filings

    View All

    SEC Form 8-K filed by Galera Therapeutics Inc.

    8-K - Galera Therapeutics, Inc. (0001563577) (Filer)

    4/3/26 6:03:35 AM ET
    $GRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 10-K/A filed by TherapeuticsMD Inc.

    10-K/A - TherapeuticsMD, Inc. (0000025743) (Filer)

    3/31/26 9:53:36 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by TherapeuticsMD Inc.

    NT 10-K - TherapeuticsMD, Inc. (0000025743) (Filer)

    3/31/26 9:48:09 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $APTX
    $CPIX
    $GRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TherapeuticsMD Announces Full Year 2025 Financial Results

    TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(0.7) million, or $(0.06) per basic and diluted common share, an improvement of $1.7 million, compared to net loss from continuing operations of $(2.3) million, or $(0.20) per basic and diluted common share, for 2024. License Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $3.0 million during the year ended Decemb

    3/30/26 4:05:00 PM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Directors

    DRAPER, Utah, March 30, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the largest independent health savings account (HSA) custodian by account volume and a leader in consumer-directed benefits (CDB), today announced that William ‘Bill' Gassen, president and chief executive officer of Sanford Health, has been elected to its board of directors (the "Board") effective March 26, 2026. He will also serve on the Audit and Risk Committee and Talent, Compensation and Culture Committee of the Board. His appointment expands the Board to 10 directors, eight of whom are independent. "Bill brings deep insight into how care is delivered, how it is financed

    3/30/26 8:30:00 AM ET
    $HQY
    $OSCR
    Real Estate
    Medical Specialities
    Health Care

    Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer

    SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions. Mr. Sisitsky brings more than 25 years of legal and governance experience advising public companies across life sciences and technology sectors.

    3/24/26 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ACAD
    $APTX
    $CPIX
    $GRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ladd Delano

    4 - HEALTHEQUITY, INC. (0001428336) (Issuer)

    4/2/26 6:12:13 PM ET
    $HQY
    Real Estate

    SEC Form 4 filed by Neeleman Stephen

    4 - HEALTHEQUITY, INC. (0001428336) (Issuer)

    4/2/26 5:16:09 PM ET
    $HQY
    Real Estate

    SEC Form 4 filed by Rosner Elimelech

    4 - HEALTHEQUITY, INC. (0001428336) (Issuer)

    4/2/26 5:11:42 PM ET
    $HQY
    Real Estate

    $ACAD
    $APTX
    $CPIX
    $GRTX
    Leadership Updates

    Live Leadership Updates

    View All

    HealthEquity Appoints Sanford Health CEO Bill Gassen to Board of Directors

    DRAPER, Utah, March 30, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ:HQY) ("HealthEquity" or the "Company"), the largest independent health savings account (HSA) custodian by account volume and a leader in consumer-directed benefits (CDB), today announced that William ‘Bill' Gassen, president and chief executive officer of Sanford Health, has been elected to its board of directors (the "Board") effective March 26, 2026. He will also serve on the Audit and Risk Committee and Talent, Compensation and Culture Committee of the Board. His appointment expands the Board to 10 directors, eight of whom are independent. "Bill brings deep insight into how care is delivered, how it is financed

    3/30/26 8:30:00 AM ET
    $HQY
    $OSCR
    Real Estate
    Medical Specialities
    Health Care

    Nathaniel Sisitsky Joins QuidelOrtho as Chief Legal Officer

    SAN DIEGO, March 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions. Mr. Sisitsky brings more than 25 years of legal and governance experience advising public companies across life sciences and technology sectors.

    3/24/26 7:00:00 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. "Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "His appointment further strengthens the Board's financial and operational expert

    3/3/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $APTX
    $CPIX
    $GRTX
    Financials

    Live finance-specific insights

    View All

    HealthEquity Reports Record Revenue, Earnings and New HSAs From Sales for Fourth Quarter and Year Ended January 31, 2026, Resulting in Raised Fiscal 2027 Outlook

    Highlights of the fiscal year include: Revenue increased 9% to $1.31 billion.Net income increased 123% to $215.2 million, and net income margin increased to 16% from 8% last year.Net income per diluted share rose to $2.46 from $1.09 one year ago, and non-GAAP net income per diluted share increased 28% to $4.00.Adjusted EBITDA increased 20% to $566.0 million, and Adjusted EBITDA margin increased to 43% from 39% last year.Total HSA Assets grew 14% to $36.5 billion.Returned $301.7 million to shareholders through stock repurchases.Further reduced HSA cash repricing risk with a cumulative $2.35 billion 5-year Treasury bond hedge at 3.92%. Highlights of the fourth quarter include: Revenue incre

    3/17/26 4:01:00 PM ET
    $HQY
    Real Estate

    Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting

    Sancuso – the Difference Between Life and LivingNASHVILLE, Tenn., March 17, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company today announced the launch of its new Sancuso® (granisetron transdermal system) website. The website is designed to provide health care professionals and patients with enhanced access to educational resources, clinical information and expert insights related to the prevention of chemotherapy-induced nausea and vomiting (CINV). The website also features the brand's key message: "Sancuso – the Difference between Life and Living."

    3/17/26 9:05:00 AM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH

    Cumberland to highlight 2025 financial, international, portfolio and clinical progressNASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $13.7 million during the fourth quarter of 2025, a 31% increase over the prior year period. Net revenues for the full year 2025 were $44.5 million an 18% increase over the prior year period, achieving the company's target of double digit revenue growth. Cumberland en

    3/3/26 5:00:00 PM ET
    $CPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $APTX
    $CPIX
    $GRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

    SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

    12/6/24 10:11:24 AM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

    SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

    11/21/24 5:10:19 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by OptiNose Inc.

    SC 13G - OptiNose, Inc. (0001494650) (Subject)

    11/20/24 5:21:26 PM ET
    $OPTN
    Biotechnology: Pharmaceutical Preparations
    Health Care